Frontlight ResearchEarly access
CompletedPhase 3
Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Infants
Key facts
- Who runs it
- Il-Yang Pharm. Co., Ltd.
- Where
- South Korea2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 260 people enrolled
- Started
- 23 Oct 2024
- Ended
- 22 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- IL-YANG FLU Vaccine Prefilled Syringe INJ.
- Fluarix Tetra Pre-filled Syringe
- Record updated
- 8 July 2026
Who can take part
- Age
- 6 months to 3 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Healthy infants 'from 6 months to under 3 years of age (≥6 months and <3 years)
- Born after normal gestation period (which is more than 37 weeks)
- A subject's legally acceptable representative has voluntarily decided on participation and provided written informed consent after receiving and understanding a detailed explanation on this study
Who cannot take part
- A history of influenza vaccination within 6 months prior to screening
- Acute fever with body temperature exceeding 38.0℃ within 72 hours prior to vaccination with the IP
- Vaccinated with other vaccines within 28 days prior to screening
- Received immunosuppressants or immune-modifying drugs within 3 months prior to screening; ① Azathioprine, cyclosporin, interferon, granulocyte colony-stimulating factor (G-CSF), tacrolimus, everolimus, sirolimus, etc; ② Use of high-dose corticosteroids (e.g., continued use of prednisolone at a dose of ≥2 mg/kg/day in subjects weighing <10 kg for 14 days or longer or at a dose of ≥20 mg/day in subjects weighing ≥10 kg for 14 days or longer). However, inhaled, intranasal, or topical corticosteroids are permitted regardless of their dose
- Prior use of immunoglobulin or blood products within 3 months prior to screening or their anticipated use during the study
- Took antipyretics, analgesics, or non-steroidal anti-inflammatory drugs (NSAIDs) within 4 hours prior to vaccination with the IP
- Participated in another clinical study within 6 months prior to screening
- A history of severe hypersensitivity reactions (e.g., anaphylaxis) to eggs, chicken, and other components of a vaccine including those derived from chicken
- Immuno dysfunction including immunodeficiency diseases or a family history thereof
- A history of Guillain-Barre syndrome
- Down's syndrome or cytogenetic disorders
- Severe chronic diseases (e.g., cardiovascular diseases excluding controlled hypertension, respiratory diseases with respiratory failure, metabolic diseases, renal dysfunction, hemoglobinopathy, etc.) that, in the opinion of investigator, preclude a subject's participation in the study
- Risk of serious bleeding from an IM injection such as hemophilia patients or those on anticoagulants
- Determined ineligible based on other clinically significant medical or psychiatric findings by the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and < 3 years)
The 2 groups in the trial
- IL-YANG FLU Vaccine Prefilled Syringe INJ.Treatment being tested
Teratect Prefilled Syringe Inj. 0.5mL
- GSK FLU Vaccine Prefilled Syringe INJ.Existing treatment, for comparison
Fluarix Tetra Pre-filled Syringe 0.5mL
Treatment: Fluarix Tetra Pre-filled Syringe
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase Ⅲ, Multi-national, Randomized, Double-blind, Active Controlled to Evaluate the Immunogenicity and Safety of "IL-YANG Quadrivalent Seasonal Influenza Vaccine" in Healthy Infants From 6 Months to Under 3 Years of Age (≥ 6 Months and < 3 Years)
- Record updated
- 8 July 2026